Interní Med. 2006; 8(4): 162-166

News in the treatment of hypertension

prof. MUDr. Jindřich ©pinar CSc., FESC, prof. MUDr. Jiří Vítovec CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

European and american guidelines For the diagnosis and treatment of hypertension were published in the year 2003, followed by Czech and British guidelines in the year 2004. These guidelines are closly simmilar, but still small differences exist. The Czech Society for Hypertension has accepted the European classification with three pre hypertension grades (optimal, normal and high normal), three grades of hypertension and isolated systolic hypertension as a specific form. Combination of antihypertensive drugs and normotension are the basic recommedations for the treatment. A good control of the systolic blood pressure and other risk factors are requested. The lowest preferable value of systolic blood pressure was not described till now. Several studies with metabolicly neutral RAAS blocade or Ca blocade strategy beeing superior to beta blocade and/or diuretics were published in the years 2002–2005.

Keywords: Key words: hypertension, diagnosis, classification, treatment, drug combinations.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. News in the treatment of hypertension. Interní Med. 2006;8(4):162-166.
Download citation

References

  1. Cífková R, Horký K, Widimský J sr, Widimský J jr, Filipovský J, Grundmann M, Monhart V, Rosolová H, Souček M, ©pinar J, Vítovec J. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2004; 50 (9): 709-722. Go to PubMed...
  2. Cobanian AV, Bakris BL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572. Go to original source... Go to PubMed...
  3. Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
  4. Fox KM; The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362:782-788. Go to original source... Go to PubMed...
  5. Janouąek S. Hypertenze u pacientů mladąích 21 let. Causa Subita 2003; 6 (7): 322-326.
  6. Julius S. za řeąitele studie VALUE: Outcomes in hypertensive patients at high risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363. Go to original source... Go to PubMed...
  7. Nissen SE, Tuzcu EM Libby P for the CAMELOT investigators: CAMELOT (Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure). JAMA 2004; 292: 2217-2226. Go to original source... Go to PubMed...
  8. Pepine C. J. for the INVEST investigators: INVEST: International Verapamil SR/Trandolapril Study. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
  9. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. Am J Cardiol. 1998; 82: 25H-30H. Go to original source... Go to PubMed...
  10. Poulter NR fot the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
  11. Seman T, Duąek J, Janda J. Arteriální hypertenze v dětském věku. Čes-Slov. Pediatr. 2003; 58 (9): 566-578.
  12. ©pinar J, Vítovec J, Zicha J. Hypertenze - diagnostika a léčba. Grada 1999: 228 s.
  13. ©pinar J, Vítovec J. Vývoj doporučení pro léčbu hypertenze. Vnitřní lékařství 2005; 51 (3): 75-82.
  14. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351: 2058-2068. Go to original source... Go to PubMed...
  15. Vítovec J, ©pinar J. Farmakoterapie kardiovaskulárních onemocnění. Grada 2004; 248 s.
  16. Widimský J, a kol. Hypertenze 2. vydání. Triton Praha 2004; 590 s.
  17. Widimský P. Studie EUROPA: Úspěch perindoprilu a české kardiologie. Cor Vasa 2004; 46: 7-8.
  18. Williams B, Poulter NR, Brown JM, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004; 328: 634-640. Go to original source... Go to PubMed...
  19. Yusuf S, Sleight P, Pogue J, et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153. Go to original source... Go to PubMed...
  20. Zanchetti A for the guidelines committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1023. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.